高钾血症治疗标准
本文综述高钾血症的治疗标准。急性高钾血症需立即稳定心肌膜、促进钾离子向细胞内转移并降低总体钾含量;慢性高钾血症需审查用药、确保有效利尿、纠正代谢性酸中毒,并重新评估限钾饮食策略,不鼓励下调肾素-血管紧张素-醛固酮抑制剂,钾结合剂和SGLT2抑制剂有助于维持这些药物使用。
要点
- 急性高钾血症需立即稳定心肌膜、促钾内移并降低总体钾。
- 慢性高钾血症需审查用药、确保利尿并纠正代谢性酸中毒。
- 限钾饮食证据不足,应侧重减少非植物来源钾摄入。
核心结论
- 急性高钾血症需紧急处理以稳定心肌膜、促进钾内移并降低总体钾含量。
- 慢性高钾血症与发病率和死亡率增加相关,需综合管理。
- 不鼓励下调或停用肾素-血管紧张素-醛固酮抑制剂,因这类药物改善心衰和蛋白尿性肾病结局。
- 钾结合剂和SGLT2抑制剂可辅助维持肾素-血管紧张素-醛固酮抑制剂的使用。
研究设计与样本
- 综述,未报告具体检索范围与样本量。
主要发现
- 急性高钾血症的严重性和风险取决于病因及血钾升高速度。
- 慢性高钾血症表现通常较轻,但仍与发病率和死亡率增加相关。
- 限制高钾食物管理高钾血症的证据缺乏,该策略正在被重新评估。
- 饮食限制应更细致,侧重减少非植物来源的钾摄入。
关键数值与推荐
- 急性高钾血症治疗初始聚焦于稳定心肌膜,随后促进钾离子向细胞内转移,最终启动降低总体钾含量的策略。
- 慢性高钾血症管理始于审查可能致病的药物、确保有效利尿治疗及纠正代谢性酸中毒(如存在)。
临床怎么用
- 急性高钾血症需立即评估并采取稳定心肌膜、促钾内移和降钾措施。
- 慢性高钾血症应审查用药、确保利尿效果并纠正代谢性酸中毒。
- 限钾饮食应侧重减少非植物来源钾,而非广泛限制高钾食物。
- 不鼓励下调或停用肾素-血管紧张素-醛固酮抑制剂,可考虑钾结合剂和SGLT2抑制剂辅助维持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperkalemia is a common electrolyte disturbance in both inpatient and outpatient clinical practice. The severity and associated risk depends on the underlying cause and rate of potassium (K+) increase. Acute hyperkalemia requires immediate attention due to potentially life-threatening manifestations resulting from the rapid increase in plasma K+ concentration. Treatment is initially focused on stabilizing the cardiac membrane, followed by maneuvers to shift K+ into the cells, and ultimately initiating strategies to decrease total body K+ content. Chronic hyperkalemia develops over a more extended period of time and manifestations tend to be less severe. Nevertheless, the disorder is not benign since chronic hyperkalemia is associated with increased morbidity and mortality. The approach to patients with chronic hyperkalemia begins with a review of medications potentially responsible for the disorder, ensuring effective diuretic therapy and correcting metabolic acidosis if present. The practice of restricting foods high in K+ to manage hyperkalemia is being reassessed since the evidence supporting the effectiveness of this strategy is lacking. Rather, dietary restriction should be more nuanced, focusing on reducing the intake of nonplant sources of K+. Down-titration and/or discontinuation of renin-angiotensin-aldosterone inhibitors should be discouraged since these drugs improve outcomes in patients with heart failure and proteinuric kidney disease. In addition to other conservative measures, K+ binding drugs and sodium-glucose cotransporter 2 inhibitors can assist in maintaining the use of these drugs.
引用
- Palmer BF, Clegg DJ. Hyperkalemia treatment standard. Nephrol Dial Transplant. 2024. PMID: 38425037. doi:10.1093/ndt/gfae056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。